OP-101

N/A

Report date: 2025/05/22 20:00:09
NME

Base Information

Drug NameOP-101
Drug Alias NameOP-101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFree radicals inhibitorsInhibitor of NF-kappa-B kinase (IKK) inhibitorsNuclear factor NF-kappa-B complex inhibitors
TargetsFree radicalsInhibitor of NF-kappa-B kinase (IKK)Nuclear factor NF-kappa-B complex
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Adrenoleukodystrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAshvattha Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAshvattha TherapeuticsOrpheris Inc
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Adrenoleukodystrophy

Other Information

ATC CodeN/A
Related LinksN/A